Effect of Morning versus Bedtime Telmisartan on Ambulatory Blood Pressure and Exercise Response in Diabetic Hypertensive Patients: A Randomised Cross-over Trial.

Bedtime telmisartan dosing significantly reduced nocturnal systolic and diastolic blood pressure compared to morning dosing.

• Forty diabetic hypertensive patients were enrolled in a randomised cross-over trial
• Each treatment period lasted 8 weeks, followed by a 1-week washout period before cross-over
• Ambulatory blood pressure monitoring was used to assess nocturnal BP
• Bedtime dosing 'considerably reduced the systolic and diastolic BP at night when compared to morning dosing'

Morning telmisartan dosing was more effective at attenuating exercise-induced blood pressure increases compared to bedtime dosing.

• Exercise BP response was assessed using treadmill exercise testing with the Bruce protocol
• Morning dosing was 'especially successful in lowering BP increases brought on by exercise'
• The study involved 40 diabetic hypertensive patients receiving telmisartan 40 mg
• This finding suggests a time-of-day-dependent effect of telmisartan on exercise hemodynamics

No noteworthy adverse events were observed with either morning or bedtime telmisartan dosing.

• Safety was assessed across both treatment arms in the 40-patient cohort
• The trial used a cross-over design, so each patient received both morning and bedtime dosing
• Telmisartan 40 mg was the dose used in both treatment periods
• 'No noteworthy adverse events were observed' in either dosing condition

Chronotherapy with telmisartan demonstrates differential effects depending on dosing time, supporting individualised treatment approaches in diabetic hypertensive patients.

• The study design was a randomised cross-over controlled trial with 40 diabetic hypertensive patients
• Circadian rhythm synchronisation was the theoretical basis for comparing morning versus bedtime dosing
• The authors conclude that 'individualised chronotherapy may improve outcomes and control hypertension in diabetic patients'
• Telmisartan is described as a 'long-acting angiotensin II receptor blocker' potentially offering advantages when timed to biological patterns